Associated Banc Corp trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 2.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 185,356 shares of the healthcare product maker’s stock after selling 5,070 shares during the quarter. Associated Banc Corp’s holdings in Abbott Laboratories were worth $11,107,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABT. BlackRock Inc. boosted its stake in shares of Abbott Laboratories by 3.3% during the fourth quarter. BlackRock Inc. now owns 110,201,384 shares of the healthcare product maker’s stock valued at $6,289,191,000 after purchasing an additional 3,566,731 shares during the period. Harding Loevner LP boosted its stake in shares of Abbott Laboratories by 73.5% during the third quarter. Harding Loevner LP now owns 4,171,941 shares of the healthcare product maker’s stock valued at $125,189,000 after purchasing an additional 1,767,384 shares during the period. Montag & Caldwell LLC purchased a new stake in shares of Abbott Laboratories during the first quarter valued at $97,503,000. DSM Capital Partners LLC boosted its stake in shares of Abbott Laboratories by 81.5% during the third quarter. DSM Capital Partners LLC now owns 3,467,401 shares of the healthcare product maker’s stock valued at $185,020,000 after purchasing an additional 1,556,566 shares during the period. Finally, Amundi Pioneer Asset Management Inc. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $66,450,000. 71.71% of the stock is owned by institutional investors.
A number of brokerages have recently issued reports on ABT. Citigroup lowered their target price on shares of Abbott Laboratories from $66.00 to $65.00 and set a “neutral” rating for the company in a research note on Tuesday, April 24th. BTIG Research reissued a “hold” rating on shares of Abbott Laboratories in a research note on Sunday, April 22nd. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a research note on Friday, April 20th. ValuEngine raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Argus boosted their target price on shares of Abbott Laboratories from $66.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, January 30th. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $68.35.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, April 18th. The healthcare product maker reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.01. The firm had revenue of $7.39 billion during the quarter, compared to the consensus estimate of $7.28 billion. Abbott Laboratories had a return on equity of 14.54% and a net margin of 1.67%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.48 earnings per share. sell-side analysts anticipate that Abbott Laboratories will post 2.86 EPS for the current fiscal year.
In other Abbott Laboratories news, insider Stephen R. Fussell sold 56,401 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $59.61, for a total value of $3,362,063.61. Following the completion of the transaction, the insider now directly owns 184,884 shares in the company, valued at $11,020,935.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jaime Contreras sold 849 shares of the business’s stock in a transaction dated Monday, April 23rd. The stock was sold at an average price of $59.36, for a total transaction of $50,396.64. Following the completion of the transaction, the insider now owns 50,436 shares of the company’s stock, valued at $2,993,880.96. The disclosure for this sale can be found here. Insiders sold 86,214 shares of company stock valued at $5,173,042 over the last 90 days. 0.74% of the stock is currently owned by corporate insiders.
Abbott Laboratories Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.